Back to results

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Primary Purpose

Angioid Streaks, Choroidal Neovascularization

Status

Unknown status

Phase

Phase 3

Locations

Mexico

Study Type

Interventional

Intervention

Intravitreal Bevacizumab

About this trial

This is an interventional treatment trial for Angioid Streaks focused on measuring Angioid Streaks, Choroidal Neovascularization, Bevacizumab

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Clinical diagnosis of Angioid Streaks
Choroidal neovascularization associated
Untreated patients or patients treated once with PDT

Exclusion Criteria:

Ocular surgery excepting uncomplicated phacoemulsification
Glaucoma or any other ocular pathology

Sites / Locations

Asociación para Evitar la Ceguera en México (APEC)

Outcomes

Primary Outcome Measures

BCVA

Fluoresceine Angiography

Optical Coherence Tomography

Secondary Outcome Measures

Full Information

NCT ID

NCT00599820

First Posted

June 30, 2006

Last Updated

January 23, 2008

Sponsor

Asociación para Evitar la Ceguera en México

1. Study Identification

Unique Protocol Identification Number

NCT00599820

Brief Title

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Official Title

OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Study Type

Interventional

2. Study Status

Record Verification Date

January 2008

Overall Recruitment Status

Unknown status

Study Start Date

November 2005 (undefined)

Primary Completion Date

undefined (undefined)

Study Completion Date

May 2006 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor

Asociación para Evitar la Ceguera en México

4. Oversight

5. Study Description

Brief Summary

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Detailed Description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Angioid Streaks, Choroidal Neovascularization

Keywords

Angioid Streaks, Choroidal Neovascularization, Bevacizumab

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

8. Arms, Groups, and Interventions

Intervention Type

Drug

Intervention Name(s)

Intravitreal Bevacizumab

Primary Outcome Measure Information:

Title

BCVA

Title

Fluoresceine Angiography

Title

Optical Coherence Tomography

10. Eligibility

Sex

All

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Clinical diagnosis of Angioid Streaks Choroidal neovascularization associated Untreated patients or patients treated once with PDT Exclusion Criteria: Ocular surgery excepting uncomplicated phacoemulsification Glaucoma or any other ocular pathology

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Adriana Solís-Vivanco, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Jans Fromow-Guerra, MD PhD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Mariana Martínez-Castellanos, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Elizabeth Reyna-Castelán, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Myriam Hernández-Rojas, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Griselda Alvarez-Rivera, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Hugo Quiroz-Mercado, MD

Organizational Affiliation

Asociación para Evitar la Ceguera en México

Official's Role

Study Director

Facility Information:

Facility Name

Asociación para Evitar la Ceguera en México (APEC)

City

México city

State/Province

Distrito Federal

ZIP/Postal Code

04030

Country

Mexico

12. IPD Sharing Statement

Learn more about this trial

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

We'll reach out to this number within 24 hrs